After Northland Securities and Needham gave Esperion (NASDAQ: ESPR) a Buy rating last month, the company received another Buy, this time from Stifel Nicolaus. Analyst Derek Archila reiterated a Buy rating on Esperion today and set a price target of $68.00. The company’s shares closed last Monday at $37.14, close to its 52-week low of $33.13.
According to TipRanks.com, Archila is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -9.6% and a 32.5% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Esperion is a Strong Buy with an average price target of $75.88, implying a 95.2% upside from current levels. In a report released today, Northland Securities also maintained a Buy rating on the stock with a $65.00 price target.
See today’s analyst top recommended stocks >>
Based on Esperion’s latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $54.22 million. In comparison, last year the company had a GAAP net loss of $49.91 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
